Matches 1 - 50 out of 276 1 2 3 4 5 6 >
Match Document Document Title
7618938 Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly  
A method for treating a cerebrovascular disease with erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) jointly by first identifying a subject in need of the treatment and then...
7601684 Diagnosis and treatment of disorders of iron metabolism  
The invention concerns a method for detecting disorders of iron metabolism and in particular the differential diagnosis of disorders of iron metabolism by means of three independent parameters. The...
7598224 Dual chain synthetic heparin-binding growth factor analogs  
The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties...
7592423 Globular adiponectin variants  
An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does...
7585943 Compositions and methods for fusion protein separation  
The present invention relates to compositions and methods for fusion protein separation utilizing a peptide linker comprising a novel thrombin cleavage site.
RE40911 Canine erythropoietin gene and recombinant protein  
One aspect of the present invention is an isolated nucleic acid molecule encoding canine erythropoietin. The present invention also relates to an isolated canine erythropoietin protein or...
7585835 GASP1: a follistatin domain containing protein  
The present invention relates to the use of a protein, GASP1, comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More...
7572763 Follistatin domain containing proteins  
The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly,...
7553940 Long-acting EPO polypeptides and derivatives thereof and methods thereof  
A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an EPO peptide are disclosed. Pharmaceutical...
7534869 Small and intermediate conductance, calcium-activated potassium channels and uses thereof  
This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and...
7531501 Method of treating endothelial injury  
The use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium (such as...
7514239 Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof  
Novel β10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods...
7514240 EGR-EGFR complex  
The present invention relates to a crystal of a complex of an epidermal growth factor (EGF) and an epidermal growth factor receptor (EGFR), a crystal of a complex of EGFR and a substance regulating...
7482427 Positive modulator of bone morphogenic protein-2  
Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are...
7479549 Recombinant canine thyroid stimulating hormone and methods of production and use thereof  
The invention includes a nucleic acid having a sequence at least 98% homologous to SEQ ID NO: 1, which encodes the α subunit of canine thyroid stimulating hormone (TSH). The invention also...
7468351 Erythropoietin solution formulation  
A stable pharmaceutical formulation of erythropoietin is disclosed which contains tris-(hydrox-ymethyl)-aminomethane as stabilizer, whereby the formulation does not contain amino acids or human...
7465447 Fc-erythropoietin fusion protein with improved pharmacokinetics  
The present invention provides Fc-erythropoietin (“Fc-EPO”) fusion proteins with improved pharmacokinetics. Nucleic acids, cells, and methods relating to the production and practice of the...
7442376 Glycoprotein hormone compositions containing two β subunits  
Forms of differentially acting glycoprotein hormones are disclosed. These compositions are of the formula β 1 -(linker 1 ) m -α-(linker...
7442684 Long-acting hormone and growth factor compositions and uses thereof  
This invention provides VEGF-FSH compounds having increased serum half-lives relative to either native VEGF or FSH, in which both VEGF and FSH are biologically active. This invention also provides...
7439063 Neuroprotective synergy of erythropoietin and insulin-like growth factors  
The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory...
7432051 Erythropoietin and erythropoietin receptor expression in human cancer  
The present invention relates to the elucidation of the role of erythropoietin and the erythropoietin receptor in the development and progression of certain solid tumors, including those found in...
7431921 Interferon beta-like molecules  
The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid...
7427486 Mullerian inhibiting substance levels and ovarian response  
Methods and kits are provided for assessing the ovarian reserve and predicting the ovarian response to fertility treatments in a female subject. The serum levels of MIS are shown to be positively...
7423139 High level expression of recombinant human erythropoietin having a modified 5′-UTR  
The present invention provides an expression construct capable of producing high levels of erythropoietin in mammalian cells. More particularly, the expression construct includes an erythropoietin...
7410941 Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin  
Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as...
7381804 G-CSF analog compositions and methods  
The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions...
7378392 Bone and cartilage inductive proteins  
Purified cartilage and/or bone inductive proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and...
7358341 Beta-like glycoprotein hormone polypeptide and heterodimer  
Novel β10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods...
7345019 Modulation of excitable tissue function by peripherally administered erythropoietin  
Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as...
7317095 Mutant glycoproteins  
The inventors have designed novel FSH mutants with increased glycosylation and longer half-lives for use in inducing folliculogenesis in human patients. The use of a FSH mutant preparation of the...
7304031 Methods and means for producing proteins with predetermined post-translational modifications  
Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the...
7304150 Methods and compositions for the prevention and treatment of anemia  
Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than...
7300915 Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain  
Erythropoietin (Epo), a member of the cytokine superfamily, is a pluripotent molecule that is involved in a number of signal transduction pathways that include the stimulation of the production of...
7268110 Agents for preventing and treating thrombocytopenia  
Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient.
7262166 Chemically modified novel erythropoietin stimulating protein compositions and methods  
The present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to novel erythropoietin stimulating protein (NESP).
7262177 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use  
A conjugate of formula A-L-P, in which: A represents a glycosylated/galactosylated peptide that binds to a cell-surface receptor, L represents a bifunctional linker, which does not comprise...
7250490 PRO1480 polypeptides  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7250493 FC fusion proteins of human erythropoietin with increased biological activities  
Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of...
7217689 Glycosylation analogs of erythropoietin  
Erythropoietin analogs having at least one additional site for glycosylation, or a rearrangement of at least one site for glycosylation are disclosed. The invention also relates to DNA sequences...
7211253 Erythropoietin forms with improved properties  
The invention relates to novel modified erythropoietin (EPO) forms such as fusion proteins comprising a Fc portion of an Ig molecule and a target molecule having the biological activity of EPO. By...
7202208 Erythropoietin composition  
The present invention relates to a liquid pharmaceutical composition consisting essentially of an erythropoietin protein, a multiple charged inorganic anion in a pharmaceutically acceptable buffer...
7196060 Method to enhance hematopoiesis  
The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to...
7166574 Synthetic heparin-binding growth factor analogs  
The invention provides synthetic heparin-binding growth factor analogs having at least one peptide chain that binds a heparin-binding growth factor receptor, covalently bound to a hydrophobic...
7157277 Factor VIII remodeling and glycoconjugation of Factor VIII  
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying...
7144574 Interferon β variants and conjugates  
The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid...
7128913 Erythropoietin conjugates  
The present invention refers to conjugates of erythropoietin with poly(ethylene glycol) comprising an erythropoietin glycoprotein having an N-terminal α-amino group and having the in vivo...
7098183 Nucleotide and amino acid sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro  
Aspects of the present invention relate to nucleotide and amino acid sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro. The present invention also concerns...
7098318 Fusion protein having enhanced in vivo activity of erythropoietin  
The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal...
7091326 Fusion protein having enhanced in vivo erythropoietin activity  
Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment...
7078376 Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects  
The invention discloses several novel therapeutic properties and methods of treatment using the recombinant erythropoietin prepared by expression from the Apa I restriction fragment of human...
Matches 1 - 50 out of 276 1 2 3 4 5 6 >